November 6, 2024
March 8, 2022
Outpatient heart failure monitoring with a novel cardiac scale: tracking volume status, Journal of American College of Cardiology, JACC
We demonstrate the ability of our Cardiac Scale to monitor the fluid status of Heart Failure patients and intervene sooner compared to using weight or symptom changes.
Download the PDF
Link to Paper
Bodyport is a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions by collecting clinically actionable biomarkers from simple, daily experiences. Bodyport captures hemodynamic signals through the Cardiac Scale to power optimized interventions tailored to the patient. By not requiring a wearable device or surgical implant, the solution seamlessly integrates into a patient’s daily life. Bodyport is focused on keeping patients with cardiorenal conditions healthier and out of the hospital. Based in San Francisco, the company is backed by top-tier investors such as Boehringer Ingelheim Venture Fund, Initialized Capital, Playground Global, Rock Health, and Y Combinator. For more information, visit bodyport.com and follow the company on LinkedIn and Twitter.
